Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/35607
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPerret, Jennifer L-
dc.contributor.authorBui, Dinh S-
dc.contributor.authorPistenmaa, Carrie-
dc.contributor.authorVicendese, Don-
dc.contributor.authorKhan, Sadiya S-
dc.contributor.authorHan, MeiLan K-
dc.contributor.authorSan José Estépar, Raul-
dc.contributor.authorLowe, Adrian J-
dc.contributor.authorLodge, Caroline J-
dc.contributor.authorLabaki, Wassim W-
dc.contributor.authorPham, Jonathan V-
dc.contributor.authorIdrose, Nur Sabrina-
dc.contributor.authorSenaratna, Chamara V-
dc.contributor.authorTan, Daniel J-
dc.contributor.authorHamilton, Garun S-
dc.contributor.authorThompson, Bruce R-
dc.contributor.authorMunsif, Maitri-
dc.contributor.authorArynchyn, Alexander-
dc.contributor.authorJacobs, David R-
dc.contributor.authorAbramson, Michael J-
dc.contributor.authorWalters, E Haydn-
dc.contributor.authorWashko, George R-
dc.contributor.authorKalhan, Ravi-
dc.contributor.authorDharmage, Shyamali C-
dc.date2024-
dc.date.accessioned2024-12-02T04:05:24Z-
dc.date.available2024-12-02T04:05:24Z-
dc.date.issued2024-11-27-
dc.identifier.citationThe Lancet. Respiratory Medicine 2024-11-27en_US
dc.identifier.issn2213-2619-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/35607-
dc.description.abstractLife-course lung function trajectories leading to airflow obstruction, as measured by impaired FEV1/FVC (forced vital capacity), precede the onset of chronic obstructive pulmonary disease (COPD). We aimed to investigate whether individuals on impaired FEV1/FVC trajectories have an increased burden of respiratory symptoms, including those who do not meet the spirometric criteria for COPD. We analysed serial life-course data from two population-based cohort studies separately, which included respiratory symptoms and spirometry: the Tasmanian Longitudinal Health Study (TAHS, Australia) cohort was recruited at age 6-7 years and followed up until middle age (mean age 53 years; range 51-55); and the Coronary Artery Risk Development in Young Adults (CARDIA, USA) cohort was recruited at a mean age of 25 years (range 18-30) and followed up to a mean age of 55 years (range 47-64). Participants' symptom profiles at ages 53 and 55 years were derived by latent class analysis. Symptom profiles were compared across pre-bronchodilator FEV1/FVC trajectories derived by group-based modelling, then restricted to those without COPD defined by post-bronchodilator airflow obstruction (FEV1/FVC <5th percentile) at ages 51-55 years and 47-64 years. Six FEV1/FVC trajectories previously derived for TAHS were replicated in CARDIA. Optimal models identified five symptom profiles in TAHS (n=2421) and six in CARDIA (n=3153). For both cohorts, the most impaired FEV1/FVC trajectory (early low, rapid decline in TAHS; low peak, rapid decline in CARDIA) was associated with predominant wheeze (multinomial odds ratio [mOR] 6·71 [95% CI 4·10-10·90] in TAHS and 9·90 [4·52-21·70] in CARDIA) and nearly all respiratory symptoms (4·95 [2·52-9·74] and 14·80 [5·97-36·60]) at age 51-55 years in TAHS and age 47-64 years in CARDIA, compared with the average trajectory. Among individuals belonging to the three most impaired trajectories, the associations with predominant wheeze increased with worsening FEV1/FVC impairment and persisted when considering only those without spirometry-defined COPD. Additionally, for those belonging to the two rapid decline trajectories, both wheezing and usual phlegm or bronchitis were reported by 54 (20%) of 265 participants younger than 14 years in TAHS and by 31 (25%) of 123 participants aged 30 years or younger in CARDIA. In two independent cohorts that collected similar data, people on impaired FEV1/FVC trajectories often had a longstanding history of both wheeze and phlegm or bronchitis, and wheeze was the predominant symptom in individuals aged 47-64 years among those who had not already progressed to COPD. National Health and Medical Research Council (Australia); The University of Melbourne; Clifford Craig Medical Research Trust; Victorian, Queensland & Tasmanian Asthma Foundations; Royal Hobart Hospital Research Foundation; Helen MacPherson Smith Trust; GlaxoSmithKline; National Heart, Lung, and Blood Institute of the US National Institutes of Health.en_US
dc.language.isoeng-
dc.titleAssociations between life-course FEV1/FVC trajectories and respiratory symptoms up to middle age: analysis of data from two prospective cohort studies.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleThe Lancet. Respiratory Medicineen_US
dc.identifier.affiliationInstitute for Breathing and Sleepen_US
dc.identifier.affiliationAllergy and Lung Health Unit, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.en_US
dc.identifier.affiliationDivision of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, USA.en_US
dc.identifier.affiliationAllergy and Lung Health Unit, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia; School of Computing, Engineering and Mathematical Sciences, La Trobe University, Bundoora, VIC, Australia.en_US
dc.identifier.affiliationDivision of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.en_US
dc.identifier.affiliationDivision of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA.en_US
dc.identifier.affiliationDepartment of Radiology, Brigham and Women's Hospital, Boston, MA, USA.en_US
dc.identifier.affiliationAllergy and Lung Health Unit, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia; Murdoch Childrens Research Institute, Parkville, VIC, Australia.en_US
dc.identifier.affiliationAllergy and Lung Health Unit, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia; Murdoch Childrens Research Institute, Parkville, VIC, Australia.en_US
dc.identifier.affiliationDivision of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA.en_US
dc.identifier.affiliationAllergy and Lung Health Unit, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia; Asthma, Allergy and Clinical Immunology (AACI) service, Department of Respiratory Medicine, Alfred Health, Melbourne, VIC, Australia.en_US
dc.identifier.affiliationAllergy and Lung Health Unit, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.en_US
dc.identifier.affiliationAllergy and Lung Health Unit, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.en_US
dc.identifier.affiliationAllergy and Lung Health Unit, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.en_US
dc.identifier.affiliationMonash Lung, Sleep, Allergy and Immunology, Monash Health, Melbourne, VIC, Australia; School of Clinical Sciences, Monash University, Melbourne, VIC, Australia.en_US
dc.identifier.affiliationMelbourne School of Health Science, The University of Melbourne, Melbourne, VIC, Australia.en_US
dc.identifier.affiliationDepartment of Respiratory and Sleep Medicine, Austin Hospital, Melbourne, VIC, Australia; Institute for Breathing and Sleep (IBAS), Melbourne, VIC, Australia.en_US
dc.identifier.affiliationSchool of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.en_US
dc.identifier.affiliationSchool of Public Health, University of Minnesota, Minneapolis, MN, USA.en_US
dc.identifier.affiliationSchool of Public Health & Preventive Medicine, Monash University, Melbourne, VIC, Australia.en_US
dc.identifier.affiliationAllergy and Lung Health Unit, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia; School of Medicine, University of Tasmania, Hobart, TAS, Australia.en_US
dc.identifier.affiliationDivision of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, USA.en_US
dc.identifier.affiliationDivision of Pulmonary and Critical Care Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.en_US
dc.identifier.affiliationAllergy and Lung Health Unit, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia; Murdoch Childrens Research Institute, Parkville, VIC, Australia.en_US
dc.identifier.doi10.1016/S2213-2600(24)00265-0en_US
dc.type.contentTexten_US
dc.identifier.pubmedid39615504-
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
crisitem.author.deptInstitute for Breathing and Sleep-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

16
checked on Dec 25, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.